^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS mutation

    i
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/14/2014
    Primary completion :
    08/25/2021
    Completion :
    01/25/2026
    HER-2 • KRAS • BRAF • NRAS • HRAS • EGF
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (NCT05853575)
    Phase 2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/16/2024
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)
    Phase 2/3
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/02/2020
    Primary completion :
    10/31/2028
    Completion :
    10/31/2029
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) (NCT05132075)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/23/2022
    Primary completion :
    10/01/2025
    Completion :
    10/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    docetaxel • opnurasib (JDQ443)
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations (NCT06043713)
    Phase 1
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/15/2023
    Primary completion :
    12/31/2025
    Completion :
    02/09/2026
    HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway (NCT05578092)
    Phase 1/2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/02/2022
    Primary completion :
    06/30/2026
    Completion :
    07/30/2026
    EGFR • KRAS • NF1 • PTPN11
    |
    KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • MRTX0902
    Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) (KRYSTAL-2) (NCT04330664)
    Phase 1
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/07/2020
    Primary completion :
    07/29/2022
    Completion :
    02/24/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • batoprotafib (TNO155)
    A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) (NCT06599502)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/18/2024
    Primary completion :
    01/20/2028
    Completion :
    01/20/2028
    KRAS
    |
    KRAS mutation • KRAS G12D
    |
    Erbitux (cetuximab)
    Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (NCT05554328)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/25/2023
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    Lynparza (olaparib) • Koselugo (selumetinib)
    Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor (AFNT211-22-101) (NCT06105021)
    Phase 1/2
    Affini-T Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/06/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2029
    KRAS
    |
    KRAS mutation • KRAS G12
    |
    AFNT-211
    Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (NCT05554367)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/13/2023
    Primary completion :
    08/26/2026
    Completion :
    08/26/2026
    KRAS • BRAF • NRAS • HRAS • RAS
    |
    BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12
    |
    Ibrance (palbociclib) • Mektovi (binimetinib)
    Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (NCT05327010)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/14/2022
    Primary completion :
    08/04/2025
    Completion :
    08/04/2025
    KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1
    |
    KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Talzenna (talazoparib) • ZEN-3694
    Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) (LUNG-MAP SUB-STUDY) (NCT06116682)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/19/2024
    Primary completion :
    05/31/2028
    Completion :
    05/31/2028
    EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Rybrevant (amivantamab-vmjw) • amivantamab SC (Ami-LC)
    Ladarixin With Sotorasib in Advanced NSCLC (NCT05815173)
    Phase 1
    NYU Langone Health
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    08/01/2023
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    KRAS • ALK • RET • ROS1
    |
    KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
    |
    Lumakras (sotorasib) • ladarixin (DF-2156A)
    A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors (IMM1104-101) (NCT05585320)
    Phase 1/2
    Immuneering Corporation
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/31/2022
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    KRAS • HRAS • APC
    |
    KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • IMM-1-104
    Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) (NCT04526691)
    Phase 1
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    09/15/2020
    Primary completion :
    04/15/2026
    Completion :
    04/15/2026
    EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan)
    A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus (NCT06056024)
    Phase 1
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/06/2023
    Primary completion :
    05/26/2027
    Completion :
    05/26/2027
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification
    Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (NCT04708054)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/21/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1
    |
    TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation
    |
    Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan
    Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (LUNG-MAP SUB-STUDY) (NCT06031688)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    08/08/2024
    Primary completion :
    05/31/2028
    Completion :
    05/31/2029
    EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Cyramza (ramucirumab) • Tepmetko (tepotinib)
    Survival Outcomes of Lung Cancer (NCT03647098)
    Phase N/A
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/01/2018
    Primary completion :
    12/31/2028
    Completion :
    12/31/2030
    KRAS • BRAF
    |
    KRAS mutation
    |
    pemetrexed
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (GO42144) (NCT04449874)
    Phase 1
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    07/29/2020
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • erlotinib • divarasib (RG6330) • Itovebi (inavolisib) • migoprotafib (RLY-1971)
    PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) (NCT04787341)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/15/2020
    Primary completion :
    06/15/2025
    Completion :
    12/15/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (CodeBreak101) (NCT04185883)
    Phase 1
    Amgen
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/17/2019
    Primary completion :
    04/29/2026
    Completion :
    03/13/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)
    KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) (NCT06026410)
    Phase 1
    Kura Oncology, Inc.
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/18/2023
    Primary completion :
    01/01/2027
    Completion :
    04/01/2027
    KRAS • NRAS • HRAS
    |
    KRAS mutation • HRAS mutation
    |
    Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • KO-2806
    Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (NCT04793958)
    Phase 3
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    06/24/2021
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Krazati (adagrasib) • leucovorin calcium
    Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/26/2014
    Primary completion :
    12/01/2022
    Completion :
    03/07/2025
    KRAS • NRAS • BCL2L2
    |
    KRAS mutation • NRAS mutation
    |
    Mekinist (trametinib) • navitoclax (ABT 263) • omipalisib (GSK2126458)
    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
    Phase 1/2
    Erasca, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/20/2021
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    Optimizing PTCy Dose and Timing (NCT03983850)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/09/2019
    Primary completion :
    05/31/2025
    Completion :
    05/29/2026
    KRAS • PTEN • IGH • FBXW7
    |
    KRAS mutation • RAS mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous
    Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) (NCT05178888)
    Phase 1
    Mirati Therapeutics Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    01/20/2022
    Primary completion :
    06/15/2023
    Completion :
    12/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Ibrance (palbociclib) • Krazati (adagrasib)
    A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (NCT05067283)
    Phase 1
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    12/17/2021
    Primary completion :
    08/19/2027
    Completion :
    08/19/2027
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • MK-1084
    A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma (NCT05943795)
    Phase 3
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK
    |
    KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion
    |
    docetaxel • izalontamab (SI-B001)
    Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (NCI-2018-01218) (NCT03065387)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/31/2017
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    HER-2 • KRAS • ERBB3 • ERBB4
    |
    KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)
    Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors (BGB-3245-AU-001) (NCT04249843)
    Phase 1
    MapKure, LLC
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/17/2020
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    KRAS • BRAF • NRAS
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (CodeBreak 100) (NCT03600883)
    Phase 1/2
    Amgen
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    08/27/2018
    Primary completion :
    05/30/2028
    Completion :
    05/30/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • midazolam hydrochloride
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (NCT01081262)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/12/2010
    Primary completion :
    02/25/2015
    Completion :
    03/01/2025
    KRAS
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • capecitabine • oxaliplatin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT01708954)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/13/2013
    Primary completion :
    08/14/2015
    Completion :
    03/07/2025
    HER-2 • KRAS • BRAF • RET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer (NCT02642042)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/18/2016
    Primary completion :
    05/15/2019
    Completion :
    03/05/2025
    KRAS • TP53 • STK11
    |
    TP53 mutation • KRAS mutation
    |
    Mekinist (trametinib) • docetaxel • omipalisib (GSK2126458)
    A Study of ASP3082 in Adults With Advanced Solid Tumors (3082-CL-0101) (NCT05382559)
    Phase 1
    Astellas Pharma Inc
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/08/2022
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • ASP3082
    Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (NCT01814501)
    Phase 2
    John Hays
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2013
    Primary completion :
    08/06/2018
    Completion :
    08/06/2018
    KRAS
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP 203) (NCT05074810)
    Phase 1/2
    Verastem, Inc.
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/12/2022
    Primary completion :
    09/01/2025
    Completion :
    04/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • avutometinib (VS-6766) • defactinib (VS-6063)